NASDAQ:LONA

Athira Pharma (LONA) Stock Price, News & Analysis

Athira Pharma logo
$2.44 -0.21 (-7.92%)
As of 02:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Athira Pharma Stock (NASDAQ:LONA)

Advanced

Key Stats

Today's Range
$2.37
▼
$2.93
50-Day Range
$2.65
▼
$7.47
52-Week Range
$2.21
▼
$14.21
Volume
73,079 shs
Average Volume
93,986 shs
Market Capitalization
$22.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Moderate Buy

Company Overview

Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

AI Generated. May Contain Errors.

Athira Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

LONA MarketRank™: 
3.41491682574 of 5 stars

Athira Pharma scored higher than 68% of companies evaluated by MarketBeat, and ranked 495th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Athira Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Athira Pharma has a consensus price target of $16.00, representing about 568.1% upside from its current price of $2.40.

  • Amount of Analyst Coverage

    Athira Pharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Athira Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Athira Pharma are expected to grow in the coming year, from ($2.67) to ($2.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athira Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athira Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Athira Pharma has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.07% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 1.13, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 14.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Athira Pharma does not currently pay a dividend.

  • Dividend Growth

    Athira Pharma does not have a long track record of dividend growth.

  • News Sentiment

    Athira Pharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Athira Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Athira Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.73% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Athira Pharma's insider trading history.
Receive LONA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LONA Stock News Headlines

Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Average Price Target of $17.00
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

LONA Stock Analysis - Frequently Asked Questions

Athira Pharma's stock was trading at $6.55 at the beginning of 2026. Since then, LONA shares have decreased by 63.4% and is now trading at $2.3950.

Athira Pharma, Inc. (NASDAQ:LONA) issued its quarterly earnings data on Monday, November, 16th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.27.

Athira Pharma's stock reverse split before market open on Thursday, September 18th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of LONA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include NVIDIA (NVDA), Intel (INTC), Alibaba Group (BABA), Ford Motor (F), Nikola (NKLAQ), NIO (NIO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/16/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:LONA
Previous Symbol
NASDAQ:ATHA
CIK
1620463
Fax
N/A
Employees
19
Year Founded
2011

Price Target and Rating

High Price Target
$20.00
Low Price Target
$12.00
Potential Upside/Downside
+568.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-422.83%
Return on Assets
-212.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.01
Quick Ratio
7.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.98 per share
Price / Book
0.80

Miscellaneous

Outstanding Shares
9,394,000
Free Float
6,977,000
Market Cap
$22.50 million
Optionable
No Data
Beta
1.90

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:LONA) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners